€ 41.65
Key Takeaways
Risk factor
Poor trading liquidity
Profitability factor
Very favourable analyst view
About
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of PHN.MI is 82 and suggests 96% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
